CANADIAN BURDEN OF CHOROIDAL NEOVASCULARIZATION SECONDARY TO PATHOLOGIC MYOPIA: BASELINE CHARACTERISTICS OF PATIENTS

被引：0
|
作者：
Zaour, N. [1 ]
Heisel, O. [2 ]
Barbeau, M. [1 ]
Ma, P. [3 ]
机构：
[1] Novartis Pharmaceut Canada Inc, Dorval, PQ, Canada
[2] Syreon Corp, Vancouver, BC, Canada
[3] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada
来源：
VALUE IN HEALTH | 2013年 / 16卷 / 07期
关键词：
D O I：
10.1016/j.jval.2013.08.1156
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A504 / A504
页数：1
相关论文
共 50 条
  • [41] FIVE-YEAR OUTCOMES OF INTRAVITREAL RANIBIZUMAB FOR CHOROIDAL NEOVASCULARIZATION IN PATIENTS WITH PATHOLOGIC MYOPIA
    Onishi, Yuka
    Yokoi, Tae
    Kasahara, Kaori
    Yoshida, Takeshi
    Nagaoka, Natsuko
    Shinohara, Kosei
    Kaneko, Yuichiro
    Suga, Mitsuki
    Uramoto, Kengo
    Ohno-Tanaka, Akiko
    Ohno-Matsui, Kyoko
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2019, 39 (07): : 1289 - 1298
  • [42] Long-term outcomes of the intravitreal injection of ranibizumab for the treatment of choroidal neovascularization secondary to pathologic myopia
    Wasiluk, Ewa
    Wojnar, Malgorzata
    Obuchowska, Iwona
    Mariak, Zofia
    INTERNATIONAL OPHTHALMOLOGY, 2020, 40 (04) : 833 - 839
  • [43] Laser Photocoagulation, Photodynamic Therapy, and Intravitreal Bevacizumab for the Treatment of Juxtafoveal Choroidal Neovascularization Secondary to Pathologic Myopia
    Parodi, Maurizio Battaglia
    Iacono, Pierluigi
    Papayannis, Alexandros
    Sheth, Saumil
    Bandello, Francesco
    ARCHIVES OF OPHTHALMOLOGY, 2010, 128 (04) : 437 - 442
  • [44] Vascular endothelial growth factor inhibitor use and treatment approach for choroidal neovascularization secondary to pathologic myopia
    Pakzad-Vaezi, Kaivon
    Mehta, Hemal
    Mammo, Zaid
    Tufail, Adnan
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2016, 16 (07) : 873 - 881
  • [45] Long-term outcomes of the intravitreal injection of ranibizumab for the treatment of choroidal neovascularization secondary to pathologic myopia
    Ewa Wasiluk
    Malgorzata Wojnar
    Iwona Obuchowska
    Zofia Mariak
    International Ophthalmology, 2020, 40 : 833 - 839
  • [46] Three Years Follow-up Results of Ranibizumab Treatment for Choroidal Neovascularization Secondary to Pathologic Myopia
    Hefner, L.
    Riese, J.
    Gerding, H.
    KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE, 2013, 230 (04) : 401 - 404
  • [47] Photodynamic therapy with verteporfin for subfoveal choroidal neovascularization secondary to pathologic myopia -: Long-term study
    Pece, Alfredo
    Isola, Vincenzo
    Vadala, Maria
    Matranga, Domenica
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2006, 26 (07): : 746 - 751
  • [48] Photodynamic therapy for nonsubfoveal choroidal neovascularization in 100 eyes with pathologic myopia
    Virgili, Gianni
    Varano, Monica
    Giacomelli, Giovanni
    Arena, Maria Chiara
    Tedeschi, Massimiliano
    Pascarella, Antonella
    Catalano, Susanna
    Menchini, Ugo
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2007, 143 (01) : 77 - 82
  • [49] Diagnosis and treatment guideline for myopic choroidal neovascularization due to pathologic myopia
    Ohno-Matsui, Kyoko
    Ikuno, Yasushi
    Lai, Timothy Y. Y.
    Cheung, Chui Ming Gemmy
    PROGRESS IN RETINAL AND EYE RESEARCH, 2018, 63 : 92 - 106
  • [50] DIFFERENT DOSING OF INTRAVITREAL BEVACIZUMAB FOR CHOROIDAL NEOVASCULARIZATION BECAUSE OF PATHOLOGIC MYOPIA
    Wakabayashi, Taku
    Ikuno, Yasushi
    Gomi, Fumi
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2011, 31 (05): : 880 - 886
12345